Results 131 to 140 of about 124,392 (280)

Association Between Oral Lichen Planus and Non‐Oral Cancers: A Multicentre Case–Control SIPMO Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives This multicentre case–control study aimed to investigate the potential association between oral lichen planus (OLP) and extraoral cancers. The secondary objective included the identification of risk factors for this association. Methods The study was conducted between January 2023 and June 2024 and included 21 Italian Oral Medicine ...
Gioele Gioco   +62 more
wiley   +1 more source

Platelet Levels Associated With Bleeding Risk for Dental Interventions: A Systematic Review

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives To evaluate evidence in relation to postoperative bleeding in humans aged ≥ 16 with preoperative platelet counts < 50,000/μL, compared to those above, undergoing dental interventions. Methods Quantitative synthesis without meta‐analysis was conducted through an electronic search conducted on Ovid MEDLINE and Embase from 1946 to ...
Guang Xu David Lim   +3 more
wiley   +1 more source

Efficacy of oral versus intravenous steroids in the treatment of pediatric immune thrombocytopenic purpura: A single center experience

open access: yesActa Marisiensis - Seria Medica
Objectives: This study conducted to assess the response rate to steroid in children with acute primary ITP and compare the relative effectiveness of oral steroid to intravenous dexamethasone.
Abdullah Essam Ahmed   +1 more
doaj   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori   +9 more
wiley   +1 more source

A Case Report of Acute Hemorrhagic Edema of Infancy

open access: yesپزشکی بالینی ابن سینا, 2005
Introduction: Acute hemorrhagic edema of infancy is an acute and rare cutaneous disorder that affects children between 4 months to 2 years of age and characterized by cutaneous purpuric lesions with millimeters to centimeters diameter.
Mozhgan Safari   +2 more
doaj  

‘Why Did You Go to Buda?’: The Humanist Sodality and Mantuan’s Rustic Idyll in Bohuslaus of Hassenstein’s Ecloga sive Idyllion Budae (1503)☆

open access: yesRenaissance Studies, EarlyView.
Abstract In the late fifteenth century, the Hungarian royal court at Buda was home to a cosmopolitan community of humanists. In early modern historiography, this cultural milieu has often been interpreted as one of the new, emergent ‘centres’ of the Renaissance in East Central Europe.
Eva Plesnik
wiley   +1 more source

Representation, medical examination, and the effectiveness of underwriting: Evidence from a life and health insurance company

open access: yesRisk Management and Insurance Review, EarlyView.
Abstract This study examines whether underwriting methods—representation, medical examination, extra premiums, and coverage—effectively mitigate adverse selection using data from an insurance company. Regarding representation, we focus on statements disclosing pre‐existing medical conditions.
Chia‐Ling Ho   +3 more
wiley   +1 more source

A skin lesion after cardiac catheterization [PDF]

open access: yes, 2012
Alaminos, Miguel   +6 more
core   +2 more sources

Purpura Fulminans [PDF]

open access: yesRevista chilena de pediatría, 1983
Vieira G, Matías   +4 more
openaire   +3 more sources

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy